Lian Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lian Zhang has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
Chunmei Gong
A State Key Laboratory of Ultrasound Engineering in Medicine Co-founded by Chongqing and the Ministry of Science and Technology, Chongqing Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering , Chongqing Medical University , Chongqing , PR China
4 shared publicationsJia He
Department of Obstetrics and Gynaecology, Suining Central Hospital , Suining , China
4 shared publications- Jin Bai
A State Key Laboratory of Ultrasound Engineering in Medicine Co-founded by Chongqing and the Ministry of Science and Technology , College of Biomedical Engineering, Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University , Chongqing , People's Republic of China
4 shared publications Bin Xie
C Department of Ultrasound , Huanggang Central Hospital , Huanggang City , Hubei , China
3 shared publicationsCai Zhang
State Key Laboratory of Ultrasound Engineering in Medicine Co-founded by Chongqing and the Ministry of Science and Technology, Chongqing Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University , Chongqing , China
3 shared publicationsJian Wang
Department of Gynecology, Chongqing Haifu Hospital, Chongqing, China
3 shared publications
Latest Publications
- Open Access
- 1 November 2025
- Published by Thong Nhat Hospital in Tạp chí Sức khỏe và Lão hóa
- Vol. 1 (5) , 11-23
CURRENT APPLICATIONS, CLINICAL EFFICACY, AND FUTURE DIRECTIONS OF HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION SURGERY IN THERAPEUTIC MEDICINE
Surgical treatment has been the standard of care in selected cases with solid tumors or uterine benign diseases. However, a majority of patients are unable to undergo surgical resection because of the tumor locations, advanced stages, or poor general condition. For patients who are not suitable for surgery or unwilling to undergo surgical treatment, high-intensity focused ultrasound (HIFU) ablation surgery is a new option. HIFU is a novel non-invasive technique that can generate coagulative necrosis at a precise focal point within the body, without damaging to the surrounding structures of the target lesions, even within the path of the beam. Ultrasound guided HIFU (USgHIFU) was first used in the treatment of bone tumors in the 1990s. Over the last two decades, this technology has made significant progress and is now widely used in the treatment of various solid tumors and benign diseases of certain organs. Currently, both magnetic resonance imaging guidance focused ultrasound surgery (MRgFUS) and USgHIFU are commercially available. Each of these two types of HIFU systems has its own advantages in guidance. USgHIFU has higher treatment efficiency, with shorter treatment time, and can treat a wider range of diseases than that of MRgFUS. Recently, HIFU has been proven to be beneficial as an adjunct in the treatment of cardiovascular diseases. In addition, MRgFUS allows for non-invasive treatment of intracranial lesions is another significant advancement in the field of therapeutic ultrasound. Histotripsy was recently approved by the U.S. Food and Drug Administration (FDA) for hepatic targets. Last year, the Focused Ultrasound Foundation announced that focused ultrasound has been used for the treatment of over 170 diseases. As advances in engineering technology, including guidance techniques for the fusion of ultrasound and MRI, as well as optimization of transducer, are making HIFU treatments easier, safer, and more efficacious. This technique may play a key role in future clinical practice.
- 1 November 2025
- Published by Thong Nhat Hospital in Tạp chí Sức khỏe và Lão hóa
- Vol. 1 (5) , 11-23
Open AccessCURRENT APPLICATIONS, CLINICAL EFFICACY, AND FUTURE DIRECTIONS OF HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION SURGERY IN THERAPEUTIC MEDICINE
Surgical treatment has been the standard of care in selected cases with solid tumors or uterine benign diseases. However, a majority of patients are unable to undergo surgical resection because of the tumor locations, advanced stages, or poor general condition. For patients who are not suitable for surgery or unwilling to undergo surgical treatment, high-intensity focused ultrasound (HIFU) ablation surgery is a new option. HIFU is a novel non-invasive technique that can generate coagulative necrosis at a precise focal point within the body, without damaging to the surrounding structures of the target lesions, even within the path of the beam. Ultrasound guided HIFU (USgHIFU) was first used in the treatment of bone tumors in the 1990s. Over the last two decades, this technology has made significant progress and is now widely used in the treatment of various solid tumors and benign diseases of certain organs. Currently, both magnetic resonance imaging guidance focused ultrasound surgery (MRgFUS) and USgHIFU are commercially available. Each of these two types of HIFU systems has its own advantages in guidance. USgHIFU has higher treatment efficiency, with shorter treatment time, and can treat a wider range of diseases than that of MRgFUS. Recently, HIFU has been proven to be beneficial as an adjunct in the treatment of cardiovascular diseases. In addition, MRgFUS allows for non-invasive treatment of intracranial lesions is another significant advancement in the field of therapeutic ultrasound. Histotripsy was recently approved by the U.S. Food and Drug Administration (FDA) for hepatic targets. Last year, the Focused Ultrasound Foundation announced that focused ultrasound has been used for the treatment of over 170 diseases. As advances in engineering technology, including guidance techniques for the fusion of ultrasound and MRI, as well as optimization of transducer, are making HIFU treatments easier, safer, and more efficacious. This technique may play a key role in future clinical practice.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 37 (1) , 399-403
The impact of ultrasound-guided high-intensity focused ultrasound for uterine fibroids on ovarian reserve
Objective: To evaluate the impact of ultrasound-guided high-intensity focused ultrasound (USgHIFU) for uterine fibroids on ovarian reserve in women of reproductive age. Materials and methods: From September 2015 to September 2017, 84 patients with uterine fibroids in reproductive age were enrolled from Chongqing Haifu Hospital, Three Gorges Central Hospital of Chongqing and Aegisroen obstetric gynecology Clinic of Seoul, Korea. Blood was collected before HIFU treatment and 6 months after USgHIFU treatment. The enzyme-linked immune analysis was used for assay of circulating anti-Mullerian hormone (AMH). Results: All the 84 patients were successfully treated with USgHIFU and 67 patients completed the follow-up. The median age of the 67 patients was 38 years at the time of treatment. The median AMH value before and 6 months after treatment was 1.26 ng/mL and 1.27 ng/mL, respectively. Patients who completed AMH measurements 6 months after treatment were further classified into three groups based on age, including younger than 35 years, 36 to 40 years, and older than 40 years. The median AMH values before treatment were 3.04 ng/mL, 1.73 ng/mL and 0.87 ng/mL, and the corresponding values 6 months after treatment were 3.24, 1.44 and 0.75, respectively. A significant difference in AMH level was observed in the group of patients at the age between 36 and 40 years (p < 0.05), but no significant difference in AMH levels was observed in the other two groups (p > 0.05). Conclusion: Based on our results, we conclude that USgHIFU has no influence on ovarian reserve.
- 1 January 2020
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 37 (1) , 399-403
Open AccessThe impact of ultrasound-guided high-intensity focused ultrasound for uterine fibroids on ovarian reserve
Objective: To evaluate the impact of ultrasound-guided high-intensity focused ultrasound (USgHIFU) for uterine fibroids on ovarian reserve in women of reproductive age. Materials and methods: From September 2015 to September 2017, 84 patients with uterine fibroids in reproductive age were enrolled from Chongqing Haifu Hospital, Three Gorges Central Hospital of Chongqing and Aegisroen obstetric gynecology Clinic of Seoul, Korea. Blood was collected before HIFU treatment and 6 months after USgHIFU treatment. The enzyme-linked immune analysis was used for assay of circulating anti-Mullerian hormone (AMH). Results: All the 84 patients were successfully treated with USgHIFU and 67 patients completed the follow-up. The median age of the 67 patients was 38 years at the time of treatment. The median AMH value before and 6 months after treatment was 1.26 ng/mL and 1.27 ng/mL, respectively. Patients who completed AMH measurements 6 months after treatment were further classified into three groups based on age, including younger than 35 years, 36 to 40 years, and older than 40 years. The median AMH values before treatment were 3.04 ng/mL, 1.73 ng/mL and 0.87 ng/mL, and the corresponding values 6 months after treatment were 3.24, 1.44 and 0.75, respectively. A significant difference in AMH level was observed in the group of patients at the age between 36 and 40 years (p < 0.05), but no significant difference in AMH levels was observed in the other two groups (p > 0.05). Conclusion: Based on our results, we conclude that USgHIFU has no influence on ovarian reserve.
- Open Access
- 1 January 2019
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 36 (1) , 925-930
Outcomes of subsequent pregnancies in patients following treatment of cesarean scar pregnancy with high intensity focused ultrasound followed by ultrasound-guided dilation and curettage
Objective: To evaluate the outcomes of subsequent pregnancies in patients with a history of cesarean scar pregnancy (CSP) treated with high intensity focused ultrasound (HIFU) followed by ultrasound-guided dilation and curettage (USg-D&C). Methods: A retrospective analysis was performed on data collected from 154 patients with CSP who were treated by HIFU followed by USg-D&C in Suining Central Hospital between January 2015 and January 2018. Among them, 28 patients wanted to conceive following treatment. Baseline characteristics, treatment results, intraoperative hemorrhages during USg-D&C, post-curettage serum beta human chorionic gonadotropin (β-hCG) levels and vaginal bleeding were investigated. Subsequent pregnancy outcomes, including intervals between pregnancy and treatment of CSP, complications during pregnancy, and outcomes of newborns were evaluated. Results: All patients with CSP were successfully treated by HIFU combined with USg-D&C. Of the 28 CSP patients who intended to conceive after the treatment, 23 patients (82.14%) successfully conceived. The average interval between conception and HIFU treatment was 18.38 ± 10.04 months. Eighteen patients (78.26%) had an intrauterine pregnancy, in which 12 had delivery by cesarean section, 1 had an ongoing pregnancy, and 5 had an abortion in the first trimester. Among the other 5 women, 3 had tubal ectopic pregnancy and 2 had recurrent CSP. These five patients underwent laparoscopy within the first trimester. Conclusion: HIFU followed by USg-D&C is an effective and safe treatment for patients with CSP who wish to conceive. Prospective multi-center studies with larger sample sizes and longer follow-up periods are needed to compare this treatment with others.
- 1 January 2019
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 36 (1) , 925-930
Open AccessOutcomes of subsequent pregnancies in patients following treatment of cesarean scar pregnancy with high intensity focused ultrasound followed by ultrasound-guided dilation and curettage
Objective: To evaluate the outcomes of subsequent pregnancies in patients with a history of cesarean scar pregnancy (CSP) treated with high intensity focused ultrasound (HIFU) followed by ultrasound-guided dilation and curettage (USg-D&C). Methods: A retrospective analysis was performed on data collected from 154 patients with CSP who were treated by HIFU followed by USg-D&C in Suining Central Hospital between January 2015 and January 2018. Among them, 28 patients wanted to conceive following treatment. Baseline characteristics, treatment results, intraoperative hemorrhages during USg-D&C, post-curettage serum beta human chorionic gonadotropin (β-hCG) levels and vaginal bleeding were investigated. Subsequent pregnancy outcomes, including intervals between pregnancy and treatment of CSP, complications during pregnancy, and outcomes of newborns were evaluated. Results: All patients with CSP were successfully treated by HIFU combined with USg-D&C. Of the 28 CSP patients who intended to conceive after the treatment, 23 patients (82.14%) successfully conceived. The average interval between conception and HIFU treatment was 18.38 ± 10.04 months. Eighteen patients (78.26%) had an intrauterine pregnancy, in which 12 had delivery by cesarean section, 1 had an ongoing pregnancy, and 5 had an abortion in the first trimester. Among the other 5 women, 3 had tubal ectopic pregnancy and 2 had recurrent CSP. These five patients underwent laparoscopy within the first trimester. Conclusion: HIFU followed by USg-D&C is an effective and safe treatment for patients with CSP who wish to conceive. Prospective multi-center studies with larger sample sizes and longer follow-up periods are needed to compare this treatment with others.
- Open Access
- 10 September 2018
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 35 (1) , 291-297
The impact of gestational sac size on the effectiveness and safety of high intensity focused ultrasound combined with ultrasound-guided suction curettage treatment for caesarean scar pregnancy
Objective: To evaluate the correlation between the gestational sac size and the effect and safety of high intensity focused ultrasound (HIFU) combined with ultrasound-guided suction curettage for caesarean scar pregnancy (CSP). Methods: Seventy-six patients with CSP were enrolled. Based on their gestational sac size, patients were divided into three groups: Group 1 (n = 16, 10–20 mm), Group 2 (n = 28, 21–30 mm) and Group 3 (n = 32, >30 mm). All of them were treated by HIFU combined with ultrasound-guided suction curettage. Baseline characteristics, parameters and adverse events of HIFU, and intraoperative hemorrhage during ultrasound-guided suction curettage were recorded. Results: The median treatment time and average treatment intensity of HIFU in Group 3 were significantly higher than Group 1 (p < .05); the median HIFU treatment power in Group 2 and Group 3 were both significantly higher than that of Group 1 (p < .05). The median sonication time of HIFU in Group 3 was significantly longer than patients in the other two groups (p < .05). The size of the gestational sac had a positive correlation with all the above-mentioned parameters of HIFU and blood loss during ultrasound-guided suction curettage (p < .05). No statistically significant differences were observed among the three groups in the duration of vaginal bleeding post-curettage and the time necessary for serum β-hCG to return to normal levels (p > .05). Conclusions: HIFU combined with ultrasound-guided suction curettage is a safe and effective clinical approach for CSP. Gestational sac size is a meaningful factor for predicting the efficacy and safety of HIFU treatment and hemorrhage during ultrasound-guided suction curettage.
- 10 September 2018
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 35 (1) , 291-297
Open AccessThe impact of gestational sac size on the effectiveness and safety of high intensity focused ultrasound combined with ultrasound-guided suction curettage treatment for caesarean scar pregnancy
Objective: To evaluate the correlation between the gestational sac size and the effect and safety of high intensity focused ultrasound (HIFU) combined with ultrasound-guided suction curettage for caesarean scar pregnancy (CSP). Methods: Seventy-six patients with CSP were enrolled. Based on their gestational sac size, patients were divided into three groups: Group 1 (n = 16, 10–20 mm), Group 2 (n = 28, 21–30 mm) and Group 3 (n = 32, >30 mm). All of them were treated by HIFU combined with ultrasound-guided suction curettage. Baseline characteristics, parameters and adverse events of HIFU, and intraoperative hemorrhage during ultrasound-guided suction curettage were recorded. Results: The median treatment time and average treatment intensity of HIFU in Group 3 were significantly higher than Group 1 (p < .05); the median HIFU treatment power in Group 2 and Group 3 were both significantly higher than that of Group 1 (p < .05). The median sonication time of HIFU in Group 3 was significantly longer than patients in the other two groups (p < .05). The size of the gestational sac had a positive correlation with all the above-mentioned parameters of HIFU and blood loss during ultrasound-guided suction curettage (p < .05). No statistically significant differences were observed among the three groups in the duration of vaginal bleeding post-curettage and the time necessary for serum β-hCG to return to normal levels (p > .05). Conclusions: HIFU combined with ultrasound-guided suction curettage is a safe and effective clinical approach for CSP. Gestational sac size is a meaningful factor for predicting the efficacy and safety of HIFU treatment and hemorrhage during ultrasound-guided suction curettage.
- Open Access
- 24 May 2018
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 35 (1) , 56-61
Adverse effect analysis of high-intensity focused ultrasound in the treatment of benign uterine diseases
Objective: To retrospectively analyze the adverse effects of high-intensity focused ultrasound (HIFU) in management of benign uterine diseases. Materials and methods: From 2011 to 2017, 27,053 patients with benign uterine diseases were treated with HIFU in 19 centers in China. Among them, 17,402 patients had uterine fibroids, 8434 had adenomyosis, 876 had caesarean scar pregnancies, and 341 had placenta accreta. Results: The median age, height, weight, BMI of the patients was 42 years, 158 mm, 56 kg, 22.5 kg/cm2, respectively. After HIFU treatment, 13,170 adverse events were observed. Based on society of interventional radiology classification system, these adverse events were classified as Class A (47.5030%), Class B (0.7947%), Class C (0.3327%), and Class D (0.0518%). The rate of major adverse effects (Class C&D) was 0.3844%. Major adverse effects include skin burn, leg pain, vaginal discharge or bleeding, urinary retention, acute cystitis, intrauterine infection, bowel injury, acute renal failure, deep vein thrombosis, pubic symphysis injury, post-HIFU thrombocytopenia, sciatic nerve injury, and hydronephrosis. In 2011, the annual rate of major adverse effects was 0.9565%; the incidence decreased to 0.2852% in 2017. No significant difference was observed in the rates of major adverse effects between patients with uterine fibroids, adenomyosis and placenta accreta. Conclusions: Based on the results with low rate of major adverse effects from multiple centers, we concluded that HIFU is safe in treating patients with benign uterine diseases. With development of this technique and more experience on the part of the physicians, the rates of the major adverse effects will be further lowered.
- 24 May 2018
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 35 (1) , 56-61
Open AccessAdverse effect analysis of high-intensity focused ultrasound in the treatment of benign uterine diseases
Objective: To retrospectively analyze the adverse effects of high-intensity focused ultrasound (HIFU) in management of benign uterine diseases. Materials and methods: From 2011 to 2017, 27,053 patients with benign uterine diseases were treated with HIFU in 19 centers in China. Among them, 17,402 patients had uterine fibroids, 8434 had adenomyosis, 876 had caesarean scar pregnancies, and 341 had placenta accreta. Results: The median age, height, weight, BMI of the patients was 42 years, 158 mm, 56 kg, 22.5 kg/cm2, respectively. After HIFU treatment, 13,170 adverse events were observed. Based on society of interventional radiology classification system, these adverse events were classified as Class A (47.5030%), Class B (0.7947%), Class C (0.3327%), and Class D (0.0518%). The rate of major adverse effects (Class C&D) was 0.3844%. Major adverse effects include skin burn, leg pain, vaginal discharge or bleeding, urinary retention, acute cystitis, intrauterine infection, bowel injury, acute renal failure, deep vein thrombosis, pubic symphysis injury, post-HIFU thrombocytopenia, sciatic nerve injury, and hydronephrosis. In 2011, the annual rate of major adverse effects was 0.9565%; the incidence decreased to 0.2852% in 2017. No significant difference was observed in the rates of major adverse effects between patients with uterine fibroids, adenomyosis and placenta accreta. Conclusions: Based on the results with low rate of major adverse effects from multiple centers, we concluded that HIFU is safe in treating patients with benign uterine diseases. With development of this technique and more experience on the part of the physicians, the rates of the major adverse effects will be further lowered.
- 30 August 2017
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 124 (S3) , 78-86
Enhancing ablation effects of a microbubble contrast agent on high‐intensity focused ultrasound: an experimental and clinical study
Objective: To investigate the relationship between SonoVue ablation enhancement effects on high‐intensity focused ultrasound (HIFU) and the concentration of SonoVue and timing of HIFU.Design: Two randomised controlled trials.Setting: An animal centre in a university and a gynaecological department in a university hospital in China.Population or sample: 63 rabbits and 143 patients with a solitary uterine fibroid.Methods: Among the 63 rabbits, three were assigned to the control group. The other 60 were evenly assigned to three study groups pretreated with 0.03, 0.05 or 0.07 ml/kg of SonoVue before HIFU treatment. Two points in each liver were selected to be treated with HIFU and sonication started at 10, 30, 60, 90, 120, 150, 180, 210, 250 or 300 seconds after the administration of SonoVue, respectively. The 143 patients with solitary uterine fibroids were assigned to four groups: 30 patients were treated using only HIFU; the other patients were pretreated with same dosage of SonoVue and 32, 38 and 43 were treated with HIFU at 1‐, 3‐, and 5‐minutes after administration of SonoVue, respectively.Main outcome measures: The relation between SonoVue ablation enhancement effects on HIFU and the concentration of SonoVue and timing of HIFU.Results: In the experimental study, the highest temperature and the largest necrotic volume in the liver were observed when HIFU sonication started at 60 seconds after administration of SonoVue. In the clinical study, the rate of significant grey‐scale changes in the 1‐minute SonoVue group was significantly greater than in the other three groups. The sonication time to reach massive grey‐scale changes measured in the 1‐minute SonoVue group was significantly shorter than in in the other three groups. The sonication time for ablating 1 cm3 of fibroid volume in the 1‐minute SonoVue group was significantly shorter than in the other three groups. The acoustic energy used in treating 1 mm3 of uterine fibroid in the 1‐minute SonoVue group was significantly less than that used in the other three groups. No major complications occurred in this study.Conclusions: SonoVue could safely be used to enhance the ablation effects of HIFU treatment, and the optimal time to begin HIFU sonication seems to be 1 minute after the administration of SonoVue.Tweetable SonoVue, a microbubble contrast agent, enhanced the ablation effects of HIFU treatment; the optimal time to begin HIFU sonication appears to be 1 minute after the administration of SonoVue.
- 30 August 2017
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 124 (S3) , 78-86
Enhancing ablation effects of a microbubble contrast agent on high‐intensity focused ultrasound: an experimental and clinical study
Objective: To investigate the relationship between SonoVue ablation enhancement effects on high‐intensity focused ultrasound (HIFU) and the concentration of SonoVue and timing of HIFU.Design: Two randomised controlled trials.Setting: An animal centre in a university and a gynaecological department in a university hospital in China.Population or sample: 63 rabbits and 143 patients with a solitary uterine fibroid.Methods: Among the 63 rabbits, three were assigned to the control group. The other 60 were evenly assigned to three study groups pretreated with 0.03, 0.05 or 0.07 ml/kg of SonoVue before HIFU treatment. Two points in each liver were selected to be treated with HIFU and sonication started at 10, 30, 60, 90, 120, 150, 180, 210, 250 or 300 seconds after the administration of SonoVue, respectively. The 143 patients with solitary uterine fibroids were assigned to four groups: 30 patients were treated using only HIFU; the other patients were pretreated with same dosage of SonoVue and 32, 38 and 43 were treated with HIFU at 1‐, 3‐, and 5‐minutes after administration of SonoVue, respectively.Main outcome measures: The relation between SonoVue ablation enhancement effects on HIFU and the concentration of SonoVue and timing of HIFU.Results: In the experimental study, the highest temperature and the largest necrotic volume in the liver were observed when HIFU sonication started at 60 seconds after administration of SonoVue. In the clinical study, the rate of significant grey‐scale changes in the 1‐minute SonoVue group was significantly greater than in the other three groups. The sonication time to reach massive grey‐scale changes measured in the 1‐minute SonoVue group was significantly shorter than in in the other three groups. The sonication time for ablating 1 cm3 of fibroid volume in the 1‐minute SonoVue group was significantly shorter than in the other three groups. The acoustic energy used in treating 1 mm3 of uterine fibroid in the 1‐minute SonoVue group was significantly less than that used in the other three groups. No major complications occurred in this study.Conclusions: SonoVue could safely be used to enhance the ablation effects of HIFU treatment, and the optimal time to begin HIFU sonication seems to be 1 minute after the administration of SonoVue.Tweetable SonoVue, a microbubble contrast agent, enhanced the ablation effects of HIFU treatment; the optimal time to begin HIFU sonication appears to be 1 minute after the administration of SonoVue.
- 19 May 2017
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 34 (1) , 77-86
Establishment of a scoring system for predicting the difficulty level of high-intensity focussed ultrasound ablation of uterine fibroids
Purpose: To establish a scoring system that predicts the difficulty level of high-intensity focussed ultrasound (HIFU) ablation of uterine fibroids. Materials and methods: Four hundred and twenty-two patients with fibroids were enrolled. The energy efficiency factor (EEF) and sonication time were set as dependent variables, with factors possibly affecting EEF and sonication time including age, body mass index (BMI), the volume of fibroids, the location of the uterus, the type of fibroids, the signal intensity on the T2-weighted imaging (T2WI), the enhancement type, the thickness of the rectus abdominis and the subcutaneous fat layer, the distance from the anterior/posterior surface of the fibroid to the skin, and the abdominal wall scars were set as predictors for building optimal scaling regression models. Results: The volume of the fibroids, the location of the uterus, the signal intensity on T2WI, enhancement type, rectus abdominis thickness, subcutaneous fat thickness, and distance from the anterior surface of fibroid to the skin were related to EEF. Signal intensity on T2WI, the volume of fibroids, distance from the posterior surface of fibroid to the skin, and enhancement type were related to sonication time. Models that can predict the difficulty level of HIFU for fibroids have been established: for EEF, y ′ = 0.338X ′1 − 0.231X ′2+0.156X ′3+0.167X ′4 ; for sonication time, y = 0.227X1+0.321X2+0.157X3+0.194X4. Conclusions: A scoring system for predicting the difficulty level of HIFU treatment for uterine fibroids has been established and it can be used to help select patients and to predict the sonication time for a given fibroid.
- 19 May 2017
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 34 (1) , 77-86
Establishment of a scoring system for predicting the difficulty level of high-intensity focussed ultrasound ablation of uterine fibroids
Purpose: To establish a scoring system that predicts the difficulty level of high-intensity focussed ultrasound (HIFU) ablation of uterine fibroids. Materials and methods: Four hundred and twenty-two patients with fibroids were enrolled. The energy efficiency factor (EEF) and sonication time were set as dependent variables, with factors possibly affecting EEF and sonication time including age, body mass index (BMI), the volume of fibroids, the location of the uterus, the type of fibroids, the signal intensity on the T2-weighted imaging (T2WI), the enhancement type, the thickness of the rectus abdominis and the subcutaneous fat layer, the distance from the anterior/posterior surface of the fibroid to the skin, and the abdominal wall scars were set as predictors for building optimal scaling regression models. Results: The volume of the fibroids, the location of the uterus, the signal intensity on T2WI, enhancement type, rectus abdominis thickness, subcutaneous fat thickness, and distance from the anterior surface of fibroid to the skin were related to EEF. Signal intensity on T2WI, the volume of fibroids, distance from the posterior surface of fibroid to the skin, and enhancement type were related to sonication time. Models that can predict the difficulty level of HIFU for fibroids have been established: for EEF, y ′ = 0.338X ′1 − 0.231X ′2+0.156X ′3+0.167X ′4 ; for sonication time, y = 0.227X1+0.321X2+0.157X3+0.194X4. Conclusions: A scoring system for predicting the difficulty level of HIFU treatment for uterine fibroids has been established and it can be used to help select patients and to predict the sonication time for a given fibroid.
- 22 March 2016
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 32 (5) , 496-503
Factors influencing the ablative efficiency of high intensity focused ultrasound (HIFU) treatment for adenomyosis: A retrospective study
Objectives The aim of this study was to investigate factors affecting ablative efficiency of high intensity focused ultrasound (HIFU) for adenomyosis. Materials and methods In all, 245 patients with adenomyosis who underwent ultrasound guided HIFU (USgHIFU) were retrospectively reviewed. All patients underwent dynamic contrast-enhanced magnetic resonance imaging (MRI) before and after HIFU treatment. The non-perfused volume (NPV) ratio, energy efficiency factor (EEF) and greyscale change were set as dependent variables, while the factors possibly affecting ablation efficiency were set as independent variables. These variables were used to build multiple regression models. Results A total of 245 patients with adenomyosis successfully completed HIFU treatment. Enhancement type on T1 weighted image (WI), abdominal wall thickness, volume of adenomyotic lesion, the number of hyperintense points, location of the uterus, and location of adenomyosis all had a linear relationship with the NPV ratio. Distance from skin to the adenomyotic lesion’s ventral side, enhancement type on T1WI, volume of adenomyotic lesion, abdominal wall thickness, and signal intensity on T2WI all had a linear relationship with EEF. Location of the uterus and abdominal wall thickness also both had a linear relationship with greyscale change. Conclusion The enhancement type on T1WI, signal intensity on T2WI, volume of adenomyosis, location of the uterus and adenomyosis, number of hyperintense points, abdominal wall thickness, and distance from the skin to the adenomyotic lesion’s ventral side can all be used as predictors of HIFU for adenomyosis.
- 22 March 2016
- Published by Taylor & Francis in International Journal of Hyperthermia
- Vol. 32 (5) , 496-503
Factors influencing the ablative efficiency of high intensity focused ultrasound (HIFU) treatment for adenomyosis: A retrospective study
Objectives The aim of this study was to investigate factors affecting ablative efficiency of high intensity focused ultrasound (HIFU) for adenomyosis. Materials and methods In all, 245 patients with adenomyosis who underwent ultrasound guided HIFU (USgHIFU) were retrospectively reviewed. All patients underwent dynamic contrast-enhanced magnetic resonance imaging (MRI) before and after HIFU treatment. The non-perfused volume (NPV) ratio, energy efficiency factor (EEF) and greyscale change were set as dependent variables, while the factors possibly affecting ablation efficiency were set as independent variables. These variables were used to build multiple regression models. Results A total of 245 patients with adenomyosis successfully completed HIFU treatment. Enhancement type on T1 weighted image (WI), abdominal wall thickness, volume of adenomyotic lesion, the number of hyperintense points, location of the uterus, and location of adenomyosis all had a linear relationship with the NPV ratio. Distance from skin to the adenomyotic lesion’s ventral side, enhancement type on T1WI, volume of adenomyotic lesion, abdominal wall thickness, and signal intensity on T2WI all had a linear relationship with EEF. Location of the uterus and abdominal wall thickness also both had a linear relationship with greyscale change. Conclusion The enhancement type on T1WI, signal intensity on T2WI, volume of adenomyosis, location of the uterus and adenomyosis, number of hyperintense points, abdominal wall thickness, and distance from the skin to the adenomyotic lesion’s ventral side can all be used as predictors of HIFU for adenomyosis.
- 1 November 2015
- Published by Elsevier in Ultrasonics Sonochemistry
- Vol. 27, 677-681
High-intensity focused ultrasound (HIFU) for adenomyosis: Two-year follow-up results
- 1 November 2015
- Published by Elsevier in Ultrasonics Sonochemistry
- Vol. 27, 677-681
High-intensity focused ultrasound (HIFU) for adenomyosis: Two-year follow-up results